Related Experiment Video
Updated: Feb 2, 2026

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
Published on: July 19, 2019
New drug developments in metastatic gastric cancer
Aaron C Tan1, David L Chan2, Wasek Faisal3
1Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia/National Cancer Centre Singapore, Singapore.
Abstract:
Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of metastatic gastric cancer, however results from clinical trials of numerous targeted agents have been mixed. The advent of immune checkpoint inhibitors has yielded similar promise and results from early trials are encouraging. This review provides an overview of the systemic treatment options evaluated in metastatic gastric cancer, with a focus on recent evidence from clinical trials for targeted therapies and immune checkpoint inhibitors. The failure to identify appropriate predictive biomarkers has hampered the success of many targeted therapies in gastric cancer, and a deeper understanding of specific molecular subtypes and genomic alterations may allow for more precision in the application of novel therapies. Identifying appropriate biomarkers for patient selection is essential for future clinical trials, for the most effective use of novel agents and in combination approaches to account for growing complexity of treatment options.
Related Concept Videos
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Gastric Emptying
Gastric Phase of Digestion
When food enters the stomach, it stretches the stomach walls and activates stretch receptors. This triggers local reflexes of the enteric nervous system, mediated through the myenteric plexus. These...
In Vitro Drug Release Testing: Overview, Development and Validation
Sustainable Development
Cancer

